Key statistics dashboard for Abeona Therapeutics Inc. (ABEO). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa.
Stock Data
| Price | $5.37 |
| Market Cap | $306M |
| Beta | 1.21 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -4.82 |
| Price / Book | 2.44 |
| P/S | 12.22 |
| P/FCF | -3.82 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 56.63% |
| EBIT Margin | -293.83% |
| EBITDA Margin | -279.93% |
| Operating Margin | -327.64% |
| Net Margin | -246.42% |
Financial Health
| Current Ratio | 6.63 |
| Quick Ratio | 6.40 |
| Cash Ratio | 2.27 |
| Debt / Equity | 0.16 |
| Debt / Assets | 11.07% |
| Interest Coverage | -25.25 |
Per-Share Data
| Revenue per share | 0.45 |
| Book Value per share | 2.24 |
| Cash per share | 2.57 |
| FCF per share | -1.43 |
| Tangible Book Value per share | 2.24 |
| Dividend per share | 0.00 |
Related companies: ARCT · ASMB · ELDN · FHTX · HUMA · PBYI · SGMT
Explore sector: Healthcare · Biotechnology
More sections of ABEO: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks